INTRODUCTION
The metastatic potential of a tumor is presumably contained within cells that are able to escape and disseminate from the primary lesion. Consequently, the identification of cytokeratinpositive cells (i.e., cells of epithelial origin) in the peripheral circulation and bone marrow of patients with clinically localized adenocarcinoma of the prostate has generated much interest.
These cells are hypothesized to originate from the primary tumor and represent a very early stage in the metastatic process (1) . The presence of these putative disseminated tumor cells (DTCs) in the bone marrow is particularly noteworthy, since bone metastases are a well known feature of lethal metastatic prostate cancer (2) . It seems likely that these cells are the source of metastatic disease in those patients who develop secondary tumors years after resection of the primary tumor. Thus, DTCs have become a key target for risk-association studies and experiments characterizing molecular features that underlie the phenotypic traits responsible for survival, dormancy, and ultimately proliferation in environments distinct from their origin.
There is a compelling need for improved ways to evaluate patients with clinicallylocalized prostate cancer for their risk of developing metastasis. Currently, risk is estimated by the pathological features of the primary tumor (e.g., Gleason Score and tumor stage) and PSA levels in peripheral blood (3, 4) . These predictive features are used to stratify patients into lowand high-risk groups. However, up to 50% of patients classified as high risk for progression do not develop metastasis, and ~10% of patients classified as low risk for progression subsequently develop secondary disease (5) . Thus, the need to more accurately distinguish those men who would benefit from aggressive adjuvant treatment regimes from those who could be safely treated by active surveillance is a powerful motivation to improve upon the ability to predict outcome.
To date, some studies have found a positive correlation with the presence of DTCs and risk of relapse following primary therapies for localized prostate cancer (6) (7) (8) (9) (10) , while others have not (11) (12) (13) (14) (15) (16) . Among the latter studies, Pfitzenmaier et al. (2007) found that 75% of pre-surgery patients without clinical evidence of metastatic spread, and only 11% of normal controls, harbored disseminated epithelial cells in their bone marrow. This frequency far exceeds the expected frequency of biochemical recurrence or metastasis. These results strongly suggest that the mere presence of DTCs is not indicative of risk of disease progression. Why do so many patients possess DTCs, if escape from the primary tumor is a rate-limiting step in the metastatic process? Despite the low incidence in normal controls, it is possible that the disseminated cells are not actually tumor cells. Characterization of the molecular features of disseminated cells might resolve the question of their tumor origin and provide a better understanding of their relationship with disease progression.
Low-resolution and low-throughput methods such as fluorescence in situ hybridization (FISH) (17) or conventional comparative genomic hybridization (CGH) (18) have provided some evidence that DTCs from epithelial cancers possess genomic abnormalities. However, the molecular characterization of DTCs by high-resolution techniques has been hampered by the small number of DTCs obtainable: typically fewer than 50 epithelial cells from bone-marrow aspirates are available for analysis. To date, high-resolution genomic analysis was only possible by first generating cell lines from DTCs (19) .
Given the proposed role that DTCs play in systemic disease and the paucity of genomic analyses of these cells, we have used array CGH to produce high-resolution genomic profiles of cells expressing epithelial markers isolated from the bone marrow of prostate-cancer patients.
We categorize our samples by the status of the patients from which they were acquired. Thus, our samples of disseminated cells obtained from patients with organ-confined (localized) disease are designated as LocDCs. Our samples of disseminated cells from patients with metastatic (advanced) disease are referred to as AdvDCs. Our study of genomic changes in LocDCs and AdvDCs lays the groundwork for a better understanding of the role these cells play in carcinogenesis.
MATERIALS AND METHODS
Sample acquisition. All samples were collected from patients undergoing treatment at the University of Washington Medical Center or the VA Puget Sound Health Care System after informed consent was obtained. A total of 59 prostate-cancer patients (11 patients with advanced disease and 48 patients with localized disease), participated in this study. Supplemental Table 1 gives the Gleason grade and TNM stage for 55 of the patients and chemical castration status for all advanced patients. Clinical data on 4 localized patients was unavailable. The mean (SD) age of these patients was 60.2 (7.4) years. Our use of human samples for this study was approved by the Institutional Review Boards of the participating institutions.
Just prior to radical prostatectomy, bone-marrow aspirates were collected from the upper iliac crest of all patients with localized disease. Bone-marrow aspirates were collected from advanced patients prior to any treatment for four patients and during the course of treatment for seven patients. Pools of 10-20 epithelial cells were isolated and collected into 10 μl H 2 0 based on expression of EpCAM (CD326; a pan-epithelial cell antigen) from the aspirates of each of 58 patients and from three biological replicates from the aspirate of one metastatic patient, as described previously (14) . Twenty of the 59 samples (14 from localized-and 6 from advanceddisease patients) were collected using 1:20 dilutions of both an anti-EpCAM(CD326) antibody conjugated with a fluorescein isothiocyanate isomer (Dako, Carpinteria, CA) and an anti-CD45 antibody conjugated to R-phycoerythrin (Dako) to label normal hematopoietic cells. This dual detection system was used to exclude normal lymphocytes from disseminated-epithelial-cell pools and to collect samples of normal-cell samples. These samples were analyzed by array CGH and used to define thresholds of loss and gain in disseminated-cell arrays (see Supplemental Methods and Results) and in proof-of-principle tests (see Results).
Prostate-tissue samples containing tumor were collected from the patients with localized disease following radical prostatectomy and were embedded in freezing media (Tissue-Tek OCT Compound, Sakura Finetek, Torrance, CA) and stored in liquid nitrogen. For nine patients from whom LocDCs were collected, the entire prostate was histologically evaluated (see Supplemental Table 1 for matched pairs). The area selected for molecular analysis was from the tumor, which was not multifocal in any of the cases. Tumor cells were isolated by laser-capture microdissection (LCM) from 5-μm thick tissue sections as described previously (20) . Two to four thousand cells were collected from each patient and from the normal stroma of five patients. We conducted tests to establish that RCGA and array CGH when applied to small numbers of cells give (1) consistently low levels of experimental noise, (2) acceptable dynamic range for detecting chromosomal alterations, and (3) We next demonstrated the reproducibility of our approach using three biological replicates composed of 20 DTCs each collected from a single patient with metastatic prostate cancer. Each 20-cell sample was independently isolated from bone marrow, amplified, labeled, and analyzed by array CGH. Figure 1A shows the high correlation between the normalized log 2 -ratio values of each possible pair of replicates. Numerous sites of copy-number change spanning many Mbp of genomic material were identified for this patient's samples. Figure 1B shows the considerable number of consistent deviant segments for the three replicates. Of the 3,077 BACs encompassed by alterations in one or more of these arrays, 72% (2219/3077) were identified in all three cell samples, and 88% (2716/3077) were deviant in two or more samples. Table 2 ).
The minimally overlapping regions (MORs) of copy-number change for deviations observed in at least four samples (36%) are given in Table 1 . This list of MORs includes many chromosomal locations reported in the literature as frequent alterations for primary or metastatic prostate tumors, including loss on 8p, 10q, 13q, and 16q, and gain on 8q and Xq. Our results help narrow in on the regions of interest for these prostate-cancer related alterations. We show five discrete MORs on 10q, three on 13q, three on 16q, and four on Xq. We determined that normal-cell contamination is unlikely to be responsible for the dimin- Seventeen loci showed copy-number deviation in >20% of LocDCs (Table 2, Figure 3) .
Thirteen of these loci are likely to be real chromosomal deviations because they have no overlap with deviant segments in normal-cell arrays. Losses involving 13q22 and 19q12 seen in >20% of the LocDCs encompass significantly more BACs than overlapping deviations registered in the normal-cell arrays (18 vs. 9, and 9 vs. 2 BACs respectively) and are thus also candidate tumor-related changes. We discount two deviations (gain in 4p16 and 11q13) as probable experimental artifact, because they appeared in ~20% of normal-cell arrays.
A comparison of the genomic profiles of LocDC and primary tumors indicates several overlapping regions of deviation ( Figure 3A and Table 2 Using simulated data sets, we found that three of the matched pairs have significantly more concordant changes than the number expected if the deviant segments were randomly distributed across the two genomes.
The degree of concordance we observe is unlikely to be affected by the different amplification schemes used to amplify LocDCs (RCGA) and primary tumors (WGA2) (see Supplemental Methods and Results for detailed comparisons of RGCA and WGA2). In brief, arrays produced from LNCaP DNA amplified by these two methods showed significant concordance in their sites of genomic change (p<0.0001) and no significant difference in the dynamic range of the deviant segments (p=0.4820).
Frequent LocDC alterations are often detected in AdvDCs but not vice versa.
We compared the array-CGH profiles of LocDCs and AdvDCs to look for changes that might illuminate the shared or divergent biology of these cell types. Ten (67%) of the 15 deviations observed in >20% of the LocDC samples (excluding those discounted as artifacts) were also observed in >20% of the AdvDC samples (Table 2 ). This set of loci includes loss at 8p23, one of the putative tumor suppressor containing regions on 8p (29) , which was observed in 27% (3/11) of AdvDC samples and 23% (11/48) of LocDC samples. Two of the four most prevalent changes seen in the AdvDC samples were seen in >20% of the LocDC samples. Loss at 10q26 was observed in 55% (6/11) of AdvDC samples and 25% (12/48) of LocDC samples. Loss at 16q21 was also observed in 55% (5/11) of AdvDC samples and in 31% (15/48) of the LocDC samples.
Given the remarkable degree of genomic change in AdvDCs and the more limited deviations in LocDCs, it is not surprising that the majority of deviations that we observed in >20% of AdvDC samples were deviant in fewer than 20% of LocDC samples ( Figure 3B and Supplemental Table 2 ). For example, losses that overlap with 8p12-21 and 8p22 were observed in four of the eleven (36%) AdvDC samples, five of the nine (56%) primary tumor samples, but only one of the 48 (2%) LocDC samples. Two deviations with considerable frequency differences was a gain of most of 8q (36% of AdvDCs and 10% of LocDCs) and gain of 1q32 (45% of AdvDCs and
8% of LocDCs).
Regions of frequent chromosomal alteration in DTCs and primary tumors are enriched for genes of involved in specific biological processes. We sought to determine if the chromosomal regions altered in DTCs and primary tumors impact genes of particular biological processes, based on gene ontology (GO) enrichment analysis. We considered all regions altered in >20% of the LocDC, AdvDC, or primary tumor samples (Supplemental Table 3 ), identified the genes corresponding to sites of loss or gain, and used hypergeometric tests (30) to determine if any GO categories were enriched (at a significance level of p < 0.001) in those gene sets. The enriched categories are given in Supplemental Table 4 (losses) and Table 5 (gains).
We also include a second p-value, the SimPValue, which is an indicator of those GO categories 
DISCUSSION
To the best of our knowledge, this study represents the highest resolution genome-wide analysis of changes performed directly on prostate-cancer DTCs. The genome analysis of a small number of cells was made possible by combining RCGA, a whole-genome amplification scheme developed by Klein et al. (18) , and array profiling by CGH. The use of a spotted DNA array as a CGH platform detects loss and gain at a high resolution and provides a direct link to the sequence of the human genome, a considerable improvement over conventional methods.
Our proof-of-principle studies show that it is possible to produce genomic profiles of a small number of cells that exhibit relatively low levels of experimental noise, highly concordant results between bulk DNA and samples of a small number of cells, and excellent reproducibility across biological replicates.
We demonstrate that LocDCs have real genomic deviations and are composed of tumor cells, even though the genomic deviations in the LocDC samples were generally fewer in number and showed lower dynamic range than those in primary tumors and AdvDCs. First, we see significantly more deviations in the LocDC arrays than in the arrays of a comparably small number of normal cells, arguing against experimental noise as the source of alterations in LocDCs.
Second, 80% of the deviant sites detected in >20% of the LocDC samples were previously reported in the literature as altered for prostate tumors. Third, we show significant concordance between a third of the matched pairs of LocDCs and primary tumors and that 60% (9/15) of the deviations observed in >20% of the all the LocDC samples were identified in our primary tumor samples.
AdvDCs are unmistakably tumor cells, given their numerous genomic alterations. Moreover, AdvDCs frequently possess deviations known to associate with a progressed disease state; deviations that were infrequently observed in LocDCs. A notable example is gain of 8q (36% of AdvDCs and 10% of LocDCs), an alteration associated with advanced disease and poor outcome in patients with organ-confined disease (23, 33, 34) . Regions containing the metastasis-suppressor genes MKK4 (17p12) and KAI1 (11p11.2) were each deleted in ~30% of AdvDC samples but very few of the LocDCs. One-third of our AdvDC samples and none of the LocDC samples had a high-level amplification of the region on chromosome X encompassing the androgen receptor gene, a well characterized alteration specific to advanced disease (35, 36) . Gain of 1q32 was one of the most common alterations found in AdvDCs (45%), uncommon in LocDCs (8%), and absent in our set of primary tumors. Notably, 50% of the metastatic tumors analyzed by array CGH in a parallel study also have a gain of 1q32 (Holcomb et al., in preparation) 19 , indicating that this region is likely to be associated with advanced disease. Will the small number of patients with LocDCs possessing metastases-associated alterations represent a significant proportion of progressors? Long-term follow-up studies are underway to answer this question.
Changes that we frequently observed in both AdvDCs and LocDCs might reflect their common origin or shared state of dissemination. Arguing for the latter, both DTC types showed frequent losses in 8p23, 10q, 13q, and 16q, alterations that have been frequently identified in prostate cancer (33) . Deviations found in both types of DTCs, but that were absent from our primary tumor samples might be alterations related to dissemination. These sites include losses in 10q25.1, 13q22.2-32.1, 13q32-34, and 16q21. Interestingly, the loss in 16q21 encompasses two members of the cadherin family of adhesion genes (CDH8 and CDH11). Disruption of the cadherin pathway is implicated in tumor invasiveness and disease progression for a number of carcinomas (37) . Analysis of a much larger set of matched primary and DTC samples will be needed to confirm what alterations are in fact specifically associated with dissemination.
The reduced amplitude of the genomic changes in LocDCs compared to AdvDCs and primary tumors could have several explanations. Copy-number changes can be dampened in the array-CGH readout by normal-cell contamination, abnormal ploidy, and heterogeneity. As we have shown, normal-cell contamination of our DTC samples is unlikely. Extra ploidy is also unlikely to be a factor in the LocDCs, as it is well established that most early prostate cancers, from which the LocDCs are presumably disseminated, are approximately diploid (38) .
Genomic heterogeneity of LocDCs, as is seen in prostate tumors (39) , is likely to contribute to a reduction in amplitude of LocDC alterations. Moreover, early dissemination might contribute additional heterogeneity to LocDCs relative to what might be found in the tumor itself.
Inclusion of cells that migrated before acquiring multiple genome changes in the pool of LocDCs will dilute and reduce the overall number of detected alterations relative to the primary tumor at the time of resection, which we observe. Early dissemination of LocDCs might also explain their notably infrequent possession of 8p12-22 loss, the most common copy-number alteration reported in prostate cancer (35) . Loss in this region was seen in only one of our 48 LocDC samples, in contrast with 54% of our primary tumors and 55% of our AdvDC samples.
How do our LocDC findings fit the current models of metastasis? The two predominant models are that (1) rare, highly metastatic cells within the primary tumor give rise to metastases, or (2) particular tumors, not rare cells, are prone to metastasis. In either case, the implication is that cells leave the primary tumor in possession of the molecular alterations necessary for secondary growth and survival. However, it is hard to imagine that the cells that generate secondary disease in patients many years after the removal of their primary tumor possess full metas-tatic potential (40) . Theories of tumor-cell dormancy have been proposed recently (41) (42) (43) suggesting that DTCs from primary tumors might represent a dormant population of cells that can, through selection and mutation over time, acquire key molecular changes that will permit metastatic growth (41) . Dormancy is supported by our GO analyses, which showed an enrichment of genes related to proliferation in sites of frequent alteration in our primary tumor and AdvDC samples, but not in our LocDCs, indicating that growth is not a prevailing theme in LocDC alterations. Thus, additional genomic hits would seem to be required, if LocDCs are to become overt metastases. Table 1 . Locations of minimally overlapping regions (MORs) of loss (A) and gain (B) detected in at least four of the 11 AdvDC samples. Ilona N. Holcomb Figure 1 
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